GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinocelltech Group Ltd (SHSE:688520) » Definitions » Capex-to-Operating-Income

Sinocelltech Group (SHSE:688520) Capex-to-Operating-Income : 0.53 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Sinocelltech Group Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Sinocelltech Group's Capital Expenditure for the three months ended in Mar. 2024 was ¥-122.67 Mil. Its Operating Income for the three months ended in Mar. 2024 was ¥232.80 Mil.

Hence, Sinocelltech Group's Capex-to-Operating-Income for the three months ended in Mar. 2024 was 0.53.


Sinocelltech Group Capex-to-Operating-Income Historical Data

The historical data trend for Sinocelltech Group's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinocelltech Group Capex-to-Operating-Income Chart

Sinocelltech Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial - - - - 3.25

Sinocelltech Group Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 1.56 0.63 - 0.53

Competitive Comparison of Sinocelltech Group's Capex-to-Operating-Income

For the Biotechnology subindustry, Sinocelltech Group's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinocelltech Group's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sinocelltech Group's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Sinocelltech Group's Capex-to-Operating-Income falls into.



Sinocelltech Group Capex-to-Operating-Income Calculation

Sinocelltech Group's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-505.377) / 155.527
=3.25

Sinocelltech Group's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-122.666) / 232.799
=0.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinocelltech Group  (SHSE:688520) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Sinocelltech Group Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Sinocelltech Group's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinocelltech Group (SHSE:688520) Business Description

Traded in Other Exchanges
N/A
Address
Kechuang Seventh Street, Beijing Economic and Technological Development Zone, Room 307, Building 5, Courtyard 31, Beijing, CHN, 100176
Sinocelltech Group Ltd is engaged in development and industrialization of biopharmaceutical products such as monoclonal antibodies, recombinant proteins and vaccines. The company has developed technology platforms in protein expression vectors, cell line development, serum-free medium development, stoichiometrically controlled fed-batch cell culture, process scale-up, and protein purification. Its capacities include stable CHO cell line development, cell banking and certification, serum-free and protein-free culture medium development, fed-batch cell culture process development, optimization, and process scale-up; protein purification development, and large scale production.
Executives
Xie Liang Zhi Director

Sinocelltech Group (SHSE:688520) Headlines

No Headlines